SWM
PRQR icon

Spire Wealth Management’s ProQR Therapeutics PRQR Stock Holding History

Spire Wealth Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,001
Closed -$16K – 2799
2021
Q4 		$16K Buy
+2,001
New +$15.2K ﹤0.01% 2208

Other funds holding PRQR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Spire Wealth Management's PRQR Position: Q1 2022 in Review

Spire Wealth Management sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 2,001 shares — an estimated $16K sold.

Spire Wealth Management first reported a position in PRQR in Q4 2021 and held it in 1 quarter. The position peaked at $16K in Q4 2021. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

  • Spire Wealth Management reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 2,001 ProQR Therapeutics shares in Q1 2022, an estimated $16K.
  • Spire Wealth Management first reported a position in ProQR Therapeutics in Q4 2021 and held it in 1 quarter.
  • Spire Wealth Management's ProQR Therapeutics position peaked at $16K in Q4 2021.
  • 58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.